Hepatitis C: Screening, treatment and prevention: Practical guidelines

Acta Gastro-Enterologica Belgica

Volumn 66, Issue 1, 2003, Pages 15-19

  Michielsen, Peter ^a   Brenard, R ^a   Bourgeois, N ^a   De Galocsy, Ch ^a   Delwaide, J ^a   Henrion, J ^a   Horsmans, Y ^a   Nevens, F ^a   Reynaert, H ^a   Robaeys, G ^a   Sprengers, D ^a   Van Vlierberghe, H ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hepatitis C; Interferon alpha; Pegylated interferon alpha; Prevention; Screening

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

BLOOD TRANSFUSION; DISEASE TRANSMISSION; HEPATITIS C; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; PRACTICE GUIDELINE; REVIEW; SCREENING; SEXUAL TRANSMISSION;

HEPATITIS C; HUMANS;

EID: 12244274965     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. World Health Organisation Weekly Epidemiological Record 49, 1999.
2. VAN DAMME P., THYSSEN A., VAN LOOCK F. Epidemiology of hepatittis C in Belgium: present and future. Acta Gastroenterol. Belg., 2002, 65: 78-79.
3. MATHEÏ C., BUNTINX F., VAN DAMME P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J. Viral Hepat., 2002, 9: 157-173.
4. DENIS B., DEDOBBELEER M., COLLET T., PETIT J., JAMOULLE M., HAYANI A., BRENARD R. High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the "Cotton filter" in transmission: the GEMT study. Acta Gastroenterol. Belg., 2000, 63: 147-153.
5. NIH Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology, 1997, 26 (suppl. 1): 2S-10S.
6. ARMSTRONG G.L., ALTER M.J., MC QUILLAN G.M., MARGOLIS H.S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology, 2000, 31: 777-782.
7. SCHAFER D.F., SORRELL M.F. Conquering hepatitis C, step by step, N. Engl. J. Med., 2000, 343: 1723-1724.
8. Conference de consensus. Traitement de l'hépatite C. /Consensus Conference. Treatment of hepatitis C. Gastroenterol. Clin. Biol., 2002, 26: B303-B319.
9. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002 - June 10-12, 2002, Hepatology, 2002, 5 (Suppl. 1): S3-S20.
10. DELWAIDE J., BOURGEOIS N., COLLE I., ROBAEYS G. Risk factors for hepatitis C: past, present and future. Acta Gastroenterol. Belg., 2002, 65: 87-89.
11. DELWAIDE J., GERARD C., VAIRA D., MAGGIPINTO G., RENTIER B., BELAICHE J. Hepatitis C virus transmission following invasive medical procedures. J. Intern. Med., 1999, 245: 107-108.
12. MELE E., SPADA L., SAGLIOCCA L., RAGNI P., TOSTI M., MOIRAGHI A., BALOCCHINI E., SNGALLI M., LOPALCO P., STROFFOLINI T. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. J. Hepatol., 2001, 35: 284-289.
13. GORDON F.D. Cost-effectiveness of screening patients for hepatitis C. Am. J. Med., 1999, 107: 36S-40S.
14. MANNS M.P., McHUTCHISON J.G., GORDON S.C., RUSTGI V.K., SHIFFMAN M., REINDOLLAR R., GOODMAN Z.D., KOURY K., LING M.-H., ALBRECHT J.K., INTERNATIONAL HEPATITIS INTERVENTIONAL THERAPY GROUP. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358: 958-965.
15. FRIED M.W., SHIFFMAN M., REDDY K.R., SMITH C., MARINOS G., GONÇALEZ F.R. Jr., HÄUSSINGER D., DIAGO M., CAROSI G., DHUMEAUX D., CRAXÍ A., LIN A., HOFFMAN J., YU J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 2002, 347: 975-982.
16. McHUTCHISON J.G., MANNS M., PATEL K., POYNARD T., LINDSAY K.L., TREPO C., DIENSTAG J., LEE W.M., MAK C., GARAUD J.-J., ALBRECHT J.K., for the International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123: 1061-1069.
17. HADZIYANNIS S., CHEINQUER H., MORGAN T., DIAGO M., JENSEN D.M., SETTE H. Jr., RAMADORI G., BODENHEIMER H.C., MARCELLIN P., LEE S.D., ACKRILL A.M. Peginterferon alfa-2a (40KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining the effect of duration of treatment and RBV dose. J. Hepatol., 2002, 36: 3 (abstract).
18. DIAGO M., HADZIYANNIS S.J., BODENHEIMER H. Jr., HASSANEIN T., UCHMAN S., MARCELLIN P., RAMADORI G., DELWAIDE J., SEDARATI F. Optimized virological response in genotype 4 chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD) (Pegays®) in combination with ribavirin (RBV). Hepatology, 2002, 36: 364 A (abstract).
19. WONG J.B., DAVIS G.L., McHUTCHISON J.G., MANNS M.P., ALBRECHT J.K. Clinical implications of testing viral response during ribavirin and peginterferon alfa-2b treatment for chronic hepatitis C. Hepatology, 2002, 36: 281A (abstract).
20. JAECKEL E., CORNBERG M., WEDEMEYER H., SANTANTONIO T., MAYER J., ZANKEL M., PASTORE G., DIETRICH M., TRAUTWEIN C., MANNS M.P., GERMAN ACUTE HEPATITIS C THERAPY GROUP. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med., 2001, 345: 1452-1457.
21. DELWAIDE J., BOURGEOIS N., GERARD C., MOKADDEM F., WAIN E., BASTENS B., FEVERY J., GEHENOT M., LEMOINE O., MARTINET J.P., PIRET ROBAEYS G., SERVAIS B., VAN GOSSUM A., VAN VLIERBERGHE H. Treatment of acute hepatitis C with interferon alpha-2b prevents chronicity. Gut, 2000, 47 (Suppl.): A14 (abstract).
22. PAWLOTSKY J. The pros of antiviral therapy in acute hepatitis C virus infection and use of antivirals for postexposure prophylaxis. In: EASL Postgraduate Course, D. SHOUVAL (ed.), Kenes International, 2002: 83-89.
23. GERBERDING J.G. Management of occupational exposures to blood-borne viruses. N. Engl. J. Med., 1995, 332: 444-451.
24. MICHIELSEN P.P., VAN DAMME P. Viral hepatitis and pregnancy. Acta Gastroenterol. Belg., 1999, 62: 21-29.
25. GIBB D., GOODALL R., HEALY M., NEAVE P., CAFFERKEY M., BUTLER K. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet, 2000, 356: 904-907.
26. OKAMOTO M., NAGATA I., MURAKAMI J., KAJI S., ITSUKA T., HOSHIKA T., MATSUDA R., TAZAWA Y., SHIRAKI K., HINO S. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high viral load, vaginal delivery, and negative anti-NS4 antibody. J. Infect. Dis., 2000, 182: 1511-1514.